EN zh-TW

newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.

biotech / news / / The Manila Times

Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented.124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be featured.

Novartis will present late-breaking Phase III results for Vanrafia (atrasentan) and Fabhalta (iptacopan) in IgAN.

KEY POINTS
COMPANIES
Read the full story on The Manila Times → →
Share X LinkedIn

Summarized by Newsio from The Manila Times. How we summarize →

RELATED 03
biotech · news · 2h 202

Cancer cells can stay hidden in the body for years before causing a relapse.

  • Breast cancer cells mimic healthy stem cells to survive undetected in bone marrow niches.
  • Notch2, but not Notch1, plays a significant role in inducing dormancy within breast cancer cells.
Drug Target Review →
biotech · news · 11h 203

Meningioma is the most common brain tumor in adults.

  • Mayo Clinic's study mapped over 500,000 individual meningioma tumor cells using single-cell sequencing.
  • Distinct immune cell states in the tumor microenvironment predict aggressiveness and recurrence risk.
News-Medical →
biotech · news · 14h 202

Scientists who study the Y chromosome expect to find a record of loss.

  • Researchers discovered a gene, Phf8y, that moved onto and duplicated within the deer mouse Y chromosome.
  • This is the first known example of a gene completing a full move onto the mammalian Y chromosome.
Earth.com →